Esketamine Hydrochloride

Dr. Aditya Vora, MD, Joins NeuPath Mind Wellness in Delray Beach, Expanding Access to Ketamine, TMS, and Advanced Psychiatry Services Every patient deserves a treatment plan that reflects their story, values, and goals. Our mission is to deliver evidence-based care that restores stability, dignity, and hope” — Dr. Aditya Vora, MD DELRAY BEACH, FL, UNITED STATES, February 18, 2026 / EINPresswire.com / -- NeuPath Mind Wellness has announced Dr. Aditya Vora, MD, as its Psychiatric Director, strengthening the practice’s commitment to advanced, evidence-based mental health treatment in Palm Beach County. Dr. Vora is a board-certified psychiatrist who combines clinical precision with a compassionate, collaborative approach to care. Originally from Long Island, New York, he moved to Florida to attend Nova Southeastern University College of Osteopathic Medicine. After completing his residency training in the state, he chose to build his professional career in Florida, serving patients across a wide range of psychiatric conditions. Clinical Focus on Complex and Treatment-Resistant Conditions: At NeuPath Mind Wellness in Delray Beach, Dr. Vora specializes in the diagnosis and treatment of attention-deficit hyperactivity disorder, anxiety and panic disorders, obsessive-compulsive disorder, major depressive disorder, bipolar disorder, and schizophrenia. His work frequently involves supporting patients facing chronic or treatment-resistant mental health challenges. His philosophy centers on helping individuals cultivate purpose, resilience, and a renewed sense of belonging. Rather than focusing solely on symptom control, Dr. Vora emphasizes long-term stability, functional improvement, and overall quality of life. A Collaborative, Culturally Responsive Approach: Dr. Vora prioritizes shared decision-making and individualized treatment planning. He works closely with patients to tailor care plans that align with their preferences and goals. Treatment options may include traditional psychiatric medication management, integrative and complementary therapies, or a carefully coordinated combination of both. NeuPath Mind Wellness provides care in a judgment-free environment that honors each patient’s cultural, racial, gender, and spiritual identity. The practice places strong emphasis on inclusivity, safety, and respect, ensuring that patients feel heard and supported throughout their treatment journey. Advanced Treatment Options Including Ketamine, TMS, and Psychiatry Services : NeuPath Mind Wellness offers Ketamine, TMS, and Psychiatry Services as part of its comprehensive approach to mental health care. The practice integrates innovative treatment modalities with structured psychiatric oversight to address conditions such as treatment-resistant depression and other complex mood disorders. Dr. Vora said: “At Neupath, I’ve seen how Spravato has opened a door for patients who have struggled with chronic, treatment-resistant depression. For many, it has provided not just a reduction in symptoms but a sense of relief and momentum when other approaches hadn’t worked. It’s been a meaningful addition to a comprehensive care plan, offering hope and tangible improvement in quality of life.” Spravato ® , an FDA-approved esketamine nasal spray, is indicated for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. At NeuPath, it is administered under medical supervision as part of a comprehensive psychiatric care plan. About NeuPath Mind Wellness: NeuPath Mind Wellness is an interventional psychiatric and mental health practice located in Delray Beach, Florida. Our multidisciplinary team blends traditional psychiatric care with interventional mental health treatments such as ketamine therapy, Spravato treatment, and TMS—all underpinned by our "root cause" approach and focus on sustainable outcomes—and delivered in our warm, serene, healing centers. By combining innovative therapies with structured psychiatric oversight, we are redefining psychiatric care for individuals who want to optimize their mental health and wellness, and overall quality of life. NeuPath aims to deliver measurable clinical outcomes while preserving the dignity, safety, and personalized care of our clients. Individuals seeking advanced mental health treatment in Delray Beach and throughout Palm Beach County are encouraged to learn more by visiting https://neupathmind.com/ , calling +1 561-847-3662, or emailing info@neupathmind.com to schedule a consultation . NeuPath Mind Wellness NeuPath Mind Wellness - Ketamine Therapy +1 561-847-3662 info@neupathmind.com Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

A psychedelic medicine for hard-to-treat depression could be under approval review before the end of this year, now that its developer has scored positive data from another large clinical trial.Compass Pathways, a London-based biotechnology company, said Tuesday it has asked to meet with the Food and Drug Administration to discuss a rolling submission of its synthetic form of psilocybin a hallucinogen-inducing compound found in certain mushroom species sometime in between October and December. Should the FDA accept that application and ultimately grant approval, the compound would become the first classic psychedelic cleared for the U.S. market.Backing Compass position are two late-stage studies that each enrolled hundreds of people with treatment-resistant depression. Results from the first of those experiments, which tested one dose of the compound against a placebo, came last summer. Though positive, they didnt live up to investor expectations, leading to a major stock sell off and Compass losing nearly half of its market value.Company shares have more than rebounded since, and at one point spiked more than 50% higher Tuesday morning, to just under $9 apiece, with the release of data from that second, twice-as-large trial.There, researchers evaluated two doses of Compass medicine, codenamed COMP360, against a far smaller dose that acted as a control group. Such a design can help address unblinding, a well-documented concern with psychedelics studies where participants deduce what arm theyve been assigned to based on whether theyre experiencing the test drugs mind-altering properties.According to Compass, six weeks into the trials treatment period, patients on the highest dose of COMP360 scored an average 3.8 points lower than those in the control group, on a 60-point scale where bigger scores signal more severe depression symptoms.Compass also said almost 40% of participants in the higher dose arm experienced a clinically meaningful reduction in depression scores at that time point. Among those patients, researchers saw a statistically significant rapid onset of the drugs effect, starting the day after administration and lasting through the six weeks.Compass expects 26-week data to become available in the third quarter.Across both experiments, the company has relied on an independent board of experts to assess safety. This board, Compass said, views the safety data seen thus far as consistent with earlier studies. No new, unexpected or concerning findings have arisen, including no evidence of a clinically meaningful imbalance between treatment arms in suicidality.This is a remarkable achievement for the field of psychiatry especially in the TRD population, where proving benefit has historically been extraordinarily challenging, said Compass CEO Kabir Nath in a statement.These data strengthen our conviction in the highly differentiated profile for COMP360, he added.Wall Street shared that enthusiasm. Ritu Baral, an analyst at TD Cowen, wrote in a note to clients that her team strongly believes Compass drug will get approved and will have robust market uptake thanks, in part, to a feasible risk-mitigation strategy.The fresh results clearly met the Street's bar for success, according to Paul Matteis of Stifel.Analysts have debated how COMP360 might compete against Johnson & Johnsons Spravato, a nasal spray form of ketamine that the FDA greenlit in 2019 for treatment-resistant depression. Spravato has, since its approval, become one of J&Js fastest-growing products, with sales increasing 57%, to $1.7 billion, last year.Spravato, because of its ketamine base and effects on the brain, isn't considered a “true“ psychedelic like psilocybin.Matteis acknowledged that investors may still nitpick Compass data, on measures like the number of participants who were partial versus full responders, or how the overall package stacks up to Spravatos.His teammates, however, are less focused on the actual raw numbers and more focused on the fact that the trials worked and the drug appears safe it's important to remember that many antidepressants, including Spravato, have been commercially successful despite multiple failed trials and COMP360 is 3-for-3, Matteis wrote in his own note. '